Topical recombinant human acidic fibroblast growth factor: An effective therapeutic agent for facemask wearing-induced pressure sores.
Dermatol Ther
; 33(4): e13745, 2020 Jul.
Article
in English
| MEDLINE | ID: covidwho-644313
ABSTRACT
Protecting health care workers is crucial during coronavirus disease 2019 pandemic and facemask wearing is considered an effective measure to prevent severe acute respiratory syndrome coronavirus 2 infection. However, long-time use of a facemask can cause pressure sores on the ears and nose bridge and increase the risk of infection. The topical recombinant human acidic fibroblast growth factor (rh-aFGF) was used to cure pressure sores for health care workers at Zhongfaxincheng campus of Tongji Hospital. The results from a small sample size survey conducted in Zhongfaxincheng campuses of Tongji Hospital showed that treatment with topical rh-aFGF could significantly inhibit the progression of pressure sores and accelerate the wound healing with no apparent ill-effects. Therefore, we propose that topical rh-aFGF is an effective therapeutic agent for facemask wearing-induced pressure sores and worth of popularizing and applying.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Fibroblast Growth Factor 1
/
Coronavirus Infections
/
Pressure Ulcer
/
Betacoronavirus
/
Masks
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2020
Document Type:
Article
Affiliation country:
Dth.13745
Similar
MEDLINE
...
LILACS
LIS